Roche Holding AG, commonly referred to as Roche, is a leading global healthcare company headquartered in Basel, Switzerland (CH). Founded in 1896, Roche has established itself as a pioneer in the pharmaceutical and diagnostics industries, focusing on innovative solutions for oncology, immunology, infectious diseases, and personalised medicine. With a strong presence in Europe, North America, and Asia, Roche is renowned for its commitment to research and development, producing unique products such as targeted therapies and advanced diagnostic tools. The company’s robust portfolio includes well-known medications like Herceptin and Avastin, which have transformed cancer treatment. Roche's dedication to innovation has earned it a prominent market position, consistently ranking among the top pharmaceutical companies globally. Its achievements in personalised healthcare and diagnostics underscore its role as a leader in advancing medical science and improving patient outcomes.
How does Roche Holding AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Roche Holding AG's score of 89 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Roche Holding AG reported total carbon emissions of approximately 5,600,000,000 kg CO2e, with emissions distributed across various scopes: 245,832,000 kg CO2e (Scope 1), 69,198,000 kg CO2e (Scope 2), and a significant 5,478,525,000 kg CO2e (Scope 3). The previous year, 2023, saw similar figures with total emissions of about 5,978,508,000 kg CO2e, comprising 240,266,000 kg CO2e (Scope 1), 98,480,000 kg CO2e (Scope 2), and 5,978,508,000 kg CO2e (Scope 3). Roche has set ambitious climate commitments, aiming for a 42% reduction in Scope 1 and 2 emissions and a 25% reduction in Scope 3 emissions by 2030, compared to 2022 levels. Additionally, the company has committed to achieving net-zero emissions across its entire value chain by 2045. Near-term targets include a 70% reduction in absolute Scope 1 and 2 emissions by 2029 from a 2022 baseline, alongside a 22.5% reduction in specific Scope 3 emissions categories within the same timeframe. Roche's targets are aligned with the Science Based Targets initiative (SBTi), which has validated their goals, ensuring they are consistent with the reductions necessary to limit global warming to 1.5°C. The company is also focused on engaging 70% of its suppliers by emissions to adopt science-based targets by 2029. Overall, Roche Holding AG is actively working towards significant emissions reductions and has established a comprehensive framework to address its carbon footprint, reflecting its commitment to sustainability and climate action.
Access structured emissions data, company-specific emission factors, and source documents
2016 | 2017 | 2018 | 2019 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|
Scope 1 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 320,860,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 209,660,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Roche Holding AG is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.